4-Amino-3-Chlorophenol CAS 17609-80-2 Lenvatinib Mesylate Intermediate Purity >99,0% (HPLC)
Pasokan Kimia Ruifu Lenvatinib Mesylate Intermediates Kanthi Kemurnian Dhuwur
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Metil 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Metil 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimetil-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Jeneng Kimia | 4-Amino-3-Klorofenol |
sinonim | 3-Chloro-4-Aminophenol;Lenvaint-G |
Nomer CAS | 17609-80-2 |
Nomer CAT | RF-PI1968 |
Status Simpenan | Ing Simpenan, Skala Produksi Nganti Ton |
Formula Molekul | C6H6ClNO |
Bobot Molekul | 143.57 |
Kapadhetan | 1,406±0,060 g/cm3 |
Merk | Kimia Ruifu |
Item | Spesifikasi |
Penampilan | Brown Solid Powder |
1 H NMR Spektrum | Konsisten karo Struktur |
Identifikasi-HPLC | Wektu retensi padha karo standar |
Kemurnian / Metode Analisis | > 99,0% (HPLC) |
Titik Lebur | 138.0~141.0 ℃ |
Mundhut ing Pangatusan | <1.00% |
Sisa ing Ignition | <0,30% |
Total Impurities | <1.00% |
Test Standar | Standar Perusahaan |
Panggunaan | Penengah saka Lenvatinib Mesylate (CAS: 857890-39-2) |
Paket: Botol, tas Aluminium foil, 25kg / Karton Drum, utawa miturut kabutuhan pelanggan
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan
4-Amino-3-Chlorophenol (CAS: 17609-80-2) minangka perantara farmasi penting, sing akeh digunakake ing desain lan sintesis anti-tumor, penyakit kardiovaskular, obat penyakit neurologis.4-Amino-3-Chlorophenol minangka perantara penting ing nyiapake Lenvatinib Mesylate (CAS: 857890-39-2).Dikembangake dening Eisai Inc., lenvatinib mesylate minangka inhibitor reseptor faktor pertumbuhan endothelial vaskular (VEGF) sing nduweni aktivitas nglawan subtipe VEGF 1, 2, lan 3 lan disetujoni dening FDA ing taun 2015 kanggo perawatan kanker tiroid sing beda-beda sing ana sacara lokal. ambalan, metastatik, utawa progresif lan ora nanggepi perawatan yodium radioaktif.Ing Mei 2016, FDA nyetujoni obat kasebut minangka terapi kombinasi karo everolimus kanggo perawatan karsinoma sel ginjel lanjut.Amarga VEGF (lan reseptor faktor pertumbuhan fibroblast, sing dikenal minangka FGFRs) dianggep nduweni peran ing jalur sinyal kardiovaskular, inhibisi VEGF2R lan FGFR dianggep minangka mekanisme ing mburi efek samping utama lenvatinib mesylate, yaiku hipertensi.